de Souza Luana Dias, Vendrame Célia Maria Vieira, de Jesus Amélia Ribeiro, Carvalho Márcia Dias Teixeira, Magalhães Andréa Santos, Schriefer Albert, Guimarães Luiz Henrique, Carvalho Edgar Marcelino de, Goto Hiro
Laboratório de Soroepidemiologia e Imunobiologia, Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, Avenida Dr. Enéas de Carvalho Aguiar n 470, prédio II, 4 andar, CEP 05403-000, São Paulo, SP, Brazil.
Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, BA, Brazil.
Parasit Vectors. 2016 Jun 11;9(1):335. doi: 10.1186/s13071-016-1619-x.
American tegumentary leishmaniasis (ATL) in Brazil is mostly caused by Leishmania (Viannia) braziliensis, with known forms of the disease being cutaneous (CL), mucosal (ML) and disseminated (DL) leishmaniasis. The development of the lesion in ATL is related both to the persistence of the Leishmania in the skin and to the parasite-triggered immune and inflammatory responses that ensue lesions. In this context one factor with expected role in the pathogenesis is insulin-like growth factor (IGF)-I with known effects on parasite growth and healing and inflammatory processes. In the present study, we addressed the effect of IGF-I on intracellular amastigote isolates from CL, ML and DL patients within human macrophage and we evaluated the IGF-I and IGF-binding protein-3 (IGFBP3) serum levels in patients presenting different clinical forms and controls from the endemic area.
We evaluated biological variability in the responses of intracellular amastigotes of Leishmania isolates derived from CL, ML, and DL patients from an area for ATL in response to IGF-I. Intracellular amastigote growth was evaluated using the human macrophage cell line THP-1. Arginase activity in infected cells was evaluated quantifying the generated urea concentration. Serum samples from patients and controls were assayed using chemiluminescent immunometric assay to determine IGF-I and IGFBP3 levels.
We observed an increase in intracellular parasitism upon IGF-I stimulus in 62.5 % of isolates from CL, in 85.7 % from ML and only 42.8 % from DL cases. In DL, the basal arginase activity was lower than that of CL. We then evaluated the IGF-I and IGFBP3 serum levels in patients, and we observed significantly lower levels in ML and DL than in CL and control samples.
The data suggest that IGF-I is modulated distinctly in different clinical forms of tegumentary leishmaniasis. IGF-I seemingly exerts effect on parasite growth likely contributing to its persistence in the skin in earlier phase. In addition the decreased IGF-I serum levels may affect the modulation of inflammation and lesion healing in chronic phase. In view of potential role of IGF-I in the pathogenesis of ATL we can speculate on therapeutic procedures taking into account the local IGF-I level.
巴西的美洲皮肤利什曼病(ATL)主要由巴西利什曼原虫(维阿尼利什曼原虫)引起,已知的疾病形式有皮肤型(CL)、黏膜型(ML)和播散型(DL)利什曼病。ATL病变的发展既与利什曼原虫在皮肤中的持续存在有关,也与寄生虫引发的免疫和炎症反应有关,这些反应会导致病变。在这种情况下,胰岛素样生长因子(IGF)-I在发病机制中可能发挥作用,已知其对寄生虫生长、愈合和炎症过程有影响。在本研究中,我们探讨了IGF-I对来自CL、ML和DL患者的人巨噬细胞内无鞭毛体分离株的影响,并评估了呈现不同临床形式的患者以及来自流行地区的对照者的血清IGF-I和IGF结合蛋白-3(IGFBP3)水平。
我们评估了来自ATL流行地区的CL、ML和DL患者的利什曼原虫分离株的细胞内无鞭毛体对IGF-I反应的生物学变异性。使用人巨噬细胞系THP-1评估细胞内无鞭毛体的生长。通过定量生成的尿素浓度评估感染细胞中的精氨酸酶活性。使用化学发光免疫分析法检测患者和对照者的血清样本,以确定IGF-I和IGFBP3水平。
我们观察到,在IGF-I刺激下,62.5%的CL分离株、85.7%的ML分离株和仅42.8%的DL分离株的细胞内寄生率增加。在DL中,基础精氨酸酶活性低于CL。然后我们评估了患者的血清IGF-I和IGFBP3水平,发现ML和DL患者的水平显著低于CL患者和对照样本。
数据表明,IGF-I在皮肤利什曼病的不同临床形式中受到不同的调节。IGF-I似乎对寄生虫生长有影响,可能在早期阶段有助于其在皮肤中的持续存在。此外,血清IGF-I水平降低可能会影响慢性期炎症的调节和病变愈合。鉴于IGF-I在ATL发病机制中的潜在作用,我们可以考虑根据局部IGF-I水平推测治疗方法。